Abstract
Background: The use of secondary debulking is accepted in patients with disease-free survival greater than 6 months after adjuvance with platinum, with peritoneal, lymph node and even liver recurrence, but controversy remains after the results of the latest controlled clinical trials published between 2019-2021 (GOG- 0123, DESKOPT III, SOC1).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
